Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2011-05-25 Share Issue/Capital Cha…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 3B 7 pages 71.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, terms, and application for quotation on the ASX. It references specific rules (2.7, 3.10.3, etc.) related to new issue announcements and includes a quotation agreement section. The content is regulatory in nature, focused on announcing and applying for quotation of additional securities rather than providing financial results or management commentary. This matches the definition of a Share Issue/Capital Change announcement. The document length is over 10,000 characters and contains substantive details about the securities issued, confirming it is not a mere announcement of a report but the actual filing of a new issue announcement form.
2011-05-25 English
Response to ASX Price and Volume Query 3 pages 71.1KB
Regulatory Filings
2011-05-10 English
Notification of relocation of share register 1 page
Regulatory Filings
2011-04-28 English
Appendix 4C - quarterly 9 pages 59.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 March 2011'. It contains detailed operational updates, licensing and IP activities, research and development progress, corporate matters, and a comprehensive Appendix 4C which is a consolidated statement of cash flows and other financial data for the quarter. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year, along with operational commentary, aligns with the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2011
2011-04-27 English
Genetic Technologies secures CLIA certification 2 pages 169.2KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated 27 April 2011 from Genetic Technologies Limited about securing US CLIA certification for its laboratory and the upcoming launch of its BREVAGen breast cancer risk test in the US market. The content focuses on regulatory approval, product launch readiness, and market positioning rather than financial results, management changes, or shareholder votes. It is a corporate announcement about a significant operational milestone and product launch, not a financial report, earnings release, or regulatory filing of a financial nature. The document length is 7518 characters, which is consistent with a detailed announcement but not a full report. There is no indication of financial statements, audit opinions, or detailed management discussion. Therefore, the best fitting category is Capital/Financing Update (CAP) as it relates to a significant business development and market launch that impacts the company's capital and commercial activities.
2011-04-26 English
Collaboration with global pharmaceutical company 2 pages 116.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 20 April 2011 from Genetic Technologies Limited. It announces a new product collaboration with a global pharmaceutical company for companion diagnostics in oncology. The content is a press release style announcement describing a preliminary research collaboration agreement and does not contain any financial statements, detailed financial data, or regulatory filings. It is not a report, transcript, or detailed presentation but rather a corporate news announcement about a collaboration. The document length is 4475 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of voting results, management changes, financing updates, or other specific report types. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for general regulatory announcements and miscellaneous filings that do not fit other categories.
2011-04-19 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.